Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Biomaterials. 2020 Aug 15;260:120333. doi: 10.1016/j.biomaterials.2020.120333

Scheme 1.

Scheme 1.

The “Two-pronged complex” is constructed by combining the anti-atherogenic platform of mDNP-LXR-L with SR-A siRNA. This novel “Two-pronged” approach is aimed to simultaneously deliver siRNA to knock down the expression of SR-A to reduce cholesterol influx and deliver LXR-L to increase the expression of cholesterol transporters ABCA1/ABCG1 to enhance cholesterol efflux, thus leading to atherosclerotic plaque regression.